• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 8, Issue 3
  3. Author

Online ISSN: 2515-8260

Volume8, Issue3

A Comparison of Topical Dorzolamide and Topical Nevanac in the Treatment of Central Serous Retinopathy: A Prospective Clinical Study

    Dr. Kanhaiya Lal Agrawal, Dr. Sanjeev Kumar

European Journal of Molecular & Clinical Medicine, 2021, Volume 8, Issue 3, Pages 4259-4263

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Aim: To compared the efficacy of topical dorzolamide and topical nevanac in central serous retinopathy.
Methods: This prospective study was carried out in the Department of Ophthalmology, Madhubani Medical College and Hospital, Madhubani, Bihar, India for 1 year. Total 20 patients diagnosed with acute CSR were included in this study. Patients divided into 2 equal groups, diagnosed with acute CSR relying upon visual acuity, dilated fundus examination and OCT findings. A detailed history of all the patients was taken to rule out other etiologies. Vision and central macular thickness were recorded using standard Snellen chart and optical coherence tomography respectively (OCT).
Results: On examination of group A patient, had visual acuity of 6/60, Counting fingers at 4 meters in the Right eye respectively, and central macular thickness (CMT) on OCT 420 microns to 430 microns respectively and group B Patient had a visual acuity of 6/60 in right eye and had a visual acuity of 6/60 in left eye, and central macular thickness on OCT was 433 microns to 457 microns respectively. Group A were started on Nevanac eye drops thrice daily, and Group B on Dorzolamide eye drops twice daily. All the patients were followed up on the 1st, 2nd, 3rd and 4th week. On each visit, vision, dilated fundoscopy, and OCT were performed. On follow up at 1st, 2nd, 3rd and 4th week it was observed that macular thickness in Group B reduced on a faster rate than in Group A
Conclusion: The two topical medications, i.e., nevanac and dorzolamide, to which both the patients responded well. But it was more rapid in the case of patient treated with dorzolamide.
Keywords:
  • PDF (133 K)
  • XML
(2021). A Comparison of Topical Dorzolamide and Topical Nevanac in the Treatment of Central Serous Retinopathy: A Prospective Clinical Study. European Journal of Molecular & Clinical Medicine, 8(3), 4259-4263.
Dr. Kanhaiya Lal Agrawal, Dr. Sanjeev Kumar. "A Comparison of Topical Dorzolamide and Topical Nevanac in the Treatment of Central Serous Retinopathy: A Prospective Clinical Study". European Journal of Molecular & Clinical Medicine, 8, 3, 2021, 4259-4263.
(2021). 'A Comparison of Topical Dorzolamide and Topical Nevanac in the Treatment of Central Serous Retinopathy: A Prospective Clinical Study', European Journal of Molecular & Clinical Medicine, 8(3), pp. 4259-4263.
A Comparison of Topical Dorzolamide and Topical Nevanac in the Treatment of Central Serous Retinopathy: A Prospective Clinical Study. European Journal of Molecular & Clinical Medicine, 2021; 8(3): 4259-4263.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 139
  • PDF Download: 600
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus